An experimental Ebola virus vaccine, developed in the EUA, has successfully passed the first test in humans. The vaccine generated an immune response to disease without severe side effects in 20 volunteers. This information is in the New England Journal of Medicine.
Clinical trials of the Ebola virus vaccine began in September at the National Institute of Health (NIH). The results are promising enough to conduct a larger study, involving thousands of participants in West Africa, where the current Ebola outbreak began doing damage.
The answer in 20 volunteers who received the Ebola virus vaccine “is very comparable” to that protects the virus animals, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, USA, an organization that participated in the clinical study, NIH Bethesda performed in the central area, Washington.
The vaccine developed by GlaxoSmithKline manufacturer uses a virus called common cold adenovirus that normally infects chimpanzees, genetically engineered with small traces of Ebola.
The 20 vaccinated volunteers in a clinical trial developed antibodies against Ebola. Only two of those receiving the higher dose had a short duration of fever.
The latter can be a problem, because the higher the dose required to generate immunity, the more difficult and costly will produce the vaccine in amounts necessary to tackle the outbreak in West Africa and stop their advance.
President Barack Obama plans to visit next Tuesday the center of the NIH, where they underwent clinical trials. Obama wants to congratulate the workers and encourage Congress to pass by the end of the year 6,180 million requested to contain the spread of the virus, as published in the newspaper 20minutes.
Since March were detected 15,351 cases of Ebola infections, of which 5,459 were fatal, according to the latest data from the World Health Organization (WHO). The countries most affected by the epidemic are Liberia, Sierra Leone and Guinea.
The Ebola virus vaccine is an important way of protection against epidemics that could decimate humanity.